Your session is about to expire
← Back to Search
Autologous tumor infiltrating lymphocytes (TILs) for Mesothelioma
Study Summary
This trial is testing a new way to treat cancer by infusing the patient's own white blood cells that have been altered to attack the tumor.
- Mesothelioma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What medical treatments is Autologous tumor infiltrating lymphocytes (TILs) primarily utilized for?
"Autologous tumor infiltrating lymphocytes (TILs) are a typical treatment for multiple sclerosis, but have also been known to effectively treat leukemia, myelocytic and acute retinoblastoma and histiocytic lymphoma patients."
Are more participants being recruited to this trial currently?
"According to records on clinicaltrials.gov, this particular medical trial is no longer recruiting participants and was last updated in April 2021. However, there are 1065 separate trials that are actively searching for patients at the moment."
What is the aggregate count of participants in this investigation?
"This research program is not currently recruiting patients. The first listing was posted on June 1st, 2015 and the latest update came April 11th, 2021. For those searching for other trials, there are 152 available options that involve mesothelioma malignancy and 913 studies concerning Autologous tumor infiltrating lymphocytes (TILs)."
Are there any other documented cases of Autologous tumor infiltrating lymphocytes (TILs) being utilized in clinical trials?
"Presently, 913 clinical investigations have been launched to assess the efficacy of Autologous tumor infiltrating lymphocytes (TILs). Of these trials 163 are in Phase 3. Philadelphia, Pennsylvania is where most of these studies take place; however, there are 28673 other sites running such tests."
Share this study with friends
Copy Link
Messenger